Alex Zhavoronkov works at the point where artificial intelligence meets biology, using machine learning to accelerate drug discovery and extend human lifespan. As Founder and CEO of Insilico Medicine, he has been at the forefront of applying AI to ageing research, moving longevity from theoretical science into real-world development pipelines.

His perspective centres on speed and possibility. He looks at how AI is compressing timelines in medicine, how ageing is increasingly treated as a modifiable condition, and what this means for how humans live, work and perform over longer lifespans. His work challenges traditional models of healthcare, positioning longevity as something that can be engineered, measured and scaled.

He reframes longevity not as a distant ambition, but as an active field of innovation already reshaping science, industry and the boundaries of human capability.